Search results

From WikiPathways

No page title matches

There is no page titled "COVID-19/box-main".

For more information about searching WikiPathways, see Help.

Showing below up to 20 results starting with #1.

View (previous 20) (next 20) (20 | 50 | 100 | 250 | 500)

Page text matches

• WikiPathways
  ... s="frontPagePanel redFg">Share your pathway knowledge in the fight against COVID-19</h2> ... t size=2>'''''ACCESS'' the rapidly growing [[Portal:COVID-19|collection of COVID-19 pathways]], ''CONTRIBUTE'' your time and domain knowledge about pathway bi ...
  7 KB (868 words) - 16:07, 10 May 2024
• Curation Events
  :: '''26 Mar 2020''' (16:00-17:00 CET) - Topic: COVID-19 pathway curation.
  1 KB (207 words) - 11:32, 9 March 2021
• Pathway:WP1799
  ... &lt;br&gt;Clinical efficacy of camrelizumab plus thymosin in patients with COVID-19 is evaluated in clinical trial NCT04268537.</Comment>
  309 KB (34357 words) - 16:56, 25 January 2021
• Pathway:WP1818
  ... 1986, Eriksson et al. 1995, Mushunje et al. 2003).&lt;br&gt;&lt;br&gt;The Covid-19 pandemic is an infection caused by the SARS-CoV-2 coronavirus. Severe case ...
  478 KB (56304 words) - 08:20, 7 August 2022
• Pathway:WP1835
  <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">COVID-19: combining antiviral and anti-inflammatory treatments.</bp:TITLE>
  250 KB (27607 words) - 16:29, 25 January 2021
• Pathway:WP1839
  ... inflammatory cytokines produced in the "cytokine storm syndrome" caused by COVID-19 (Cron &amp; Chatham 2020).</Comment>
  513 KB (57632 words) - 16:14, 25 January 2021
• Pathway:WP1919
  ... ed for the treatment of lung complications associated with severe cases of COVID-19 (Phase 2/3 NCT04275414) (Rosa &amp; Santos 2020).</Comment>
  652 KB (72121 words) - 16:22, 25 January 2021
• Pathway:WP4961
  ... pathvisio.org/GPML/2013a" Name="STING pathway in Kawasaki-like disease and COVID-19" Version="20200728" Organism="Homo sapiens"> The STING pathway is relevant to Kawasaki-like disease in COVID-19.
  27 KB (2644 words) - 14:05, 26 March 2024
• Pathway:WP4058
  ... py (RECOVERY) trial in June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. In the trial, dexamethasone red ...
  200 KB (22599 words) - 16:48, 25 January 2021
• Pathway:WP4419
  ... ngolimod is being investigated in the management of inflammation caused by COVID-19 (Phase 2 study NCT04280588).</Comment>
  1.14 MB (135187 words) - 09:53, 7 May 2021
• Pathway:WP4799
  ... ulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"><bp:TERM>COVID-19</bp:TERM><bp:ID>DOID:0080600</bp:ID><bp:Ontology>Disease</bp:Ontology></bp ...
  10 KB (1188 words) - 23:10, 6 March 2024
• Pathway:WP4884
  ... ays-description">Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathoge ... ... MLSchema#string">Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathoge ...
  24 KB (2390 words) - 13:05, 18 November 2022
• Pathway:WP4846
  <Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="SARS-CoV-2 and COVID-19 pathway" Version="20200316" Organism="Homo sapiens"> ... n">Collaborative project for curation biological processes involved in the COVID-19 disease after SARS-Cov-2 infection. It focuses on experimental evidence an ...
  107 KB (10725 words) - 13:52, 18 November 2022
• Pathway:WP4853
  <DataNode TextLabel="SARS-CoV-2 and &#10;COVID-19 pathway&#10;molecular mechanism" GraphId="a93c5" Type="Pathway"> <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">COVID-19 and the immune system.</bp:TITLE>
  54 KB (6200 words) - 23:27, 10 February 2024
• Pathway:WP4860
  ... /22-rdf-syntax-ns#" rdf:datatype="http://www.w3.org/2001/XMLSchema#string">COVID-19</bp:TERM>
  17 KB (2003 words) - 12:41, 18 November 2022
• Pathway:WP4868
  ... ro_domain). The antimicrobial agent, azithromycin, is in clincal trials as COVID-19 therapy in combination with hydroxychloroquine (Gautret 2020) has been sho ... ... 01/XMLSchema#string">Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.</bp:TITLE>
  108 KB (11048 words) - 23:49, 6 February 2023
• Pathway:WP4876
  ... /22-rdf-syntax-ns#" rdf:datatype="http://www.w3.org/2001/XMLSchema#string">COVID-19</bp:TERM>
  16 KB (1759 words) - 01:05, 24 January 2024
• Pathway:WP4877
  ... reveals the interferon-MAPK pathway mediated adaptive immune response for COVID-19</bp:TITLE> ... /22-rdf-syntax-ns#" rdf:datatype="http://www.w3.org/2001/XMLSchema#string">COVID-19</bp:TERM>
  48 KB (4602 words) - 22:52, 2 February 2024
• Pathway:WP4880
  ... o_domain). The antimicrobial agent, azithromycin, is in clinical trials as COVID-19 therapy in combination with hydroxychloroquine (Gautret 2020) has been sho ... ... 01/XMLSchema#string">Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.</bp:TITLE>
  65 KB (6573 words) - 12:59, 18 February 2024
• Pathway:WP4883
  <Comment>Literature curation of biological processes involved in the COVID-19 disease after SARS-Cov-2 infection and molecular mechanism and potential t ... ... /22-rdf-syntax-ns#" rdf:datatype="http://www.w3.org/2001/XMLSchema#string">COVID-19</bp:TERM>
  48 KB (4357 words) - 00:29, 19 December 2021

View (previous 20) (next 20) (20 | 50 | 100 | 250 | 500)